series-c-plus
Stage
1
Investors
About
Stayble Therapeutics is a clinical-stage pharmaceutical company developing STA363, an injectable treatment for chronic low back pain and leg pain caused by disc degeneration and herniation. The treatment aims to stabilize discs and reduce pain by transforming disc material into connective tissue.
Explore Stayble Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.